Home News

First nine months 2020 results presentation

Operating income, growth figures, profitability and how our products have behaved.

Thu, 05/11/2020 - 00:00 0 min
Download related document
No votes yet
 
Related
ROVI achieves an increase of 52% in operating income and 75% in EBITDA
Laboratorios Farmacéuticos Rovi, SA (BME: ROVI), company Pan-European pharmaceutical company specialized and dedicated to the research...
6 min
28/07/2021
First half 2021 results presentation
0 min
28/07/2021
ROVI holds its 2021 General Shareholders Meeting
ROVI holds its 2021 General Shareholders Meeting
Laboratorios Farmaceuticos Rovi, SA has held its today General Ordinary Shareholders Meeting, in which a valuation of the 2020 financial...
6 min
17/06/2021